Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02468024 · ClinicalTrials.gov registry record · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 272
- Enrollment target
- 20
- Study locations
NCT02468024: Recruiting Phase 3 study of Non-Small Cell Lung Cancer, sponsored by University of Texas Southwestern Medical Center.
NCT02468024 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 272 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02468024, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 272 participants
- Enrollment target
- 20
- Study locations
Study Summary
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Primary Outcome
To test the hypothesis that the 3-year overall survival in high risk operable patients with Stage I NSCLC is greater in patient who undergo SAbR as compared to standard sublobar resection (SR).
Conditions Studied
Interventions
- RADIATION Radiation therapy
- PROCEDURE Lung Surgery
Study Locations (20)
Colorado
- University of Colorado/Memorial - Aurora
- Penrose Cancer Center - Colorado Springs
Kentucky
- University of Kentucky Health Care - Lexington
- University of Louisville Physicians - Louisville
Maryland
- Luminis Health Research Institute - Annapolis
- University of Maryland Medical Center - Baltimore
Michigan
- Henry Ford Health System - Detroit
- Beaumont - Royal Oak
New York
- New York University Langone Medical Center - New York
- SUNY - Upsate Medical Centre - Syracuse
California
- UCSD - La Jolla
Florida
- Boca Raton Regional Hospital - Boca Raton
Georgia
- Curtis and Elizabeth Anderson Cancer - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2015-07 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What NCT02468024 shows while recruiting
NCT02468024 is an interventional study that assigns participants to a tested intervention. The registered 272 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation therapy is the first listed.
NCT02468024 names 20 study sites across 15 states, led by Colorado, Kentucky, Maryland.
Frequently Asked Questions
What is clinical trial NCT02468024 about?
NCT02468024 is a clinical study titled "JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer". To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
What is the current status of trial NCT02468024?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 272 participants. The study started on 2015-07. Estimated completion is 2028-12.
What conditions does trial NCT02468024 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02468024?
The interventions under investigation include: Radiation therapy (RADIATION), Lung Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT02468024?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02468024 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02468024's enrollment target sits among peer trials
272 138th of 454 higher than 317 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
- NCT06083051 · 272 participants · NA
Differences in Postoperative Symptoms With Four Ureteral Stents
- NCT06449638 · 272 participants · NA
Modified Platform Trial Assessing Multiple CAMPs and SOC vs SOC Alone in the Treatment of Hard-to-Heal DFUs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia